Home Analyst Ratings Sage Therapeutics Inc. gets an upgrade to a Buy from Guggenheim

Sage Therapeutics Inc. [SAGE] gets an upgrade to a Buy from Guggenheim

Guggenheim took its Sage Therapeutics Inc. [NASDAQ:SAGE]‎‎ rating to the equivalent of Buy from ‎Neutral, ‎in a research note dated January 4, 2021. Other analysts also revised their coverage, with ‎Mizuho’s analysts upgrading the shares from “a ‎Neutral” rating to “a Buy” rating in a research note to ‎investors issued in early December. Meanwhile, ‎Raymond James had lowered its rating on SAGE to ‎‎”Mkt perform” from the earlier “an Outperform”, in ‎a research note produced for clients December ‎‎01, 2020. In addition, there was a downgrade from ‎Morgan Stanley on November 16, 2020. The rater ‎changed SAGE from “an Overweight” to “an Equal-‎weight”.

Get the ‎hottest stocks to trade every day before the market ‎opens 100% free. Click here ‎now. ‎‎

Is Sage Therapeutics Inc. [NASDAQ:SAGE] a Good Buy Right ‎Now?

It should be noted that ‎SAGE technical indicators for short, intermediate as well as long ‎term progress have placed an overall ‎average of 100% as Buy. The average signal changed from 100% ‎Buy in the last week and compares ‎with 88% Buy in the past month. Data from Sage Therapeutics Inc.’s ‎Trend Spotter indicated that the ‎signals were Weakest. The stock current average is 0.65 million shares ‎in the past 20 days and the short ‎term average signal indicates a 100% Buy. In the last 50 days, the ‎average trading volume was 0.72 ‎million shares while the medium term average advocated for 100% ‎Buy. The average long-term signal ‎stands at 100% Buy and the 100-day average volume stands at 0.7 ‎million shares.‎‎

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


SAGE Price Performance

On Wall Street, Sage Therapeutics Inc. ‎‎[NASDAQ:SAGE] finished ‎Thursday’s session down -2.42% at $86.51. The stock went up to $89.16 at the ‎same session while its ‎lowest single day price was $86.25. In the last five days, it saw a fall of about -‎‎2.45%, Sage Therapeutics ‎Inc. shares gained by almost 19.84% since the beginning of the year. ‎However, the share price has ‎dropped to as low as -4.49% below its one year high. On 12/28/20, the ‎company shares recorded ‎‎$90.58, the highest single-day price it has got to in the last 52-weeks and a ‎‎52-week low was seen on ‎‎03/18/20, the same year at $25.01. The company’s shares have inclined by ‎‎18.25% in the past year. The ‎‎50-day SMA achieved is $76.25 while the 200-day SMA is $52.54. Volume ‎dropped to 0.29 million from ‎‎0.34 million in the previous session.‎‎

SAGE Stock Support And ‎Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 85.45 level, ‎and in case of violation of this particular level, it will cause more drop to ‎‎84.40 level. On the upper level, ‎‎90.22 is still the key resistance. The stock may increase to the ‎subsequent resistance at 88.36. The ‎Relative Strength Index (RSI) pinned on the 14-day chart is 64.36, ‎implying a neutral technical stance ‎while the MACD stands at 5.70, meaning price will increase in the ‎next trading period. Percent R ‎indicator moved to 18.03%, implying bullish price movement. Stochastic ‎‎%K at 86.10% suggest selling ‎the stock.‎‎

What is the short interest in Sage Therapeutics Inc.?

Short interest in the Sage ‎Therapeutics ‎Inc. stock has surged, increasing by 40000.0 shares to total 5.31 million shares on Dec 14, ‎‎2020. The ‎interest had seen shares on Nov 12, 2020 stand at 5.35 million, data from Yahoo Finance ‎shows. The ‎decrease of -0.75% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to ‎cover (short ratio) moved to while the shorted shares account for just 14.10% of the overall ‎float for ‎the stock.‎‎

Sage Therapeutics Inc.’s Biggest Shareholders: Who Owns Sage Therapeutics ‎Inc. ‎‎[SAGE]?

Filings by Fidelity Management & Research Co showed that the firm now holds a ‎total of ‎‎7,732,540 shares or roughly 14.86% of the outstanding SAGE shares. This means their shares ‎have ‎increased by 8,468 from the 7,732,540 the investor reportedly held in its prior 13-F filing. With ‎the ‎conclusion of the purchase, The Vanguard Group, Inc. updated stake is worth $329,515,942. Details ‎in ‎the latest 13F filings reveal that T. Rowe Price Associates, Inc. disposed off their -9.22% stake valued ‎at ‎‎$189,598,829 while D. E. Shaw & Co. LP added theirs at $182,488,560. During the last quarter, T. ‎Rowe ‎Price Associates, Inc. liquidated -260,018 of its shares in Sage Therapeutics Inc. while D. E. Shaw ‎& Co. ‎LP bought 340,910 shares. The BlackRock Fund Advisors’s holdings currently number 2,372,497 ‎shares ‎at $205244715.47. According to the firm’s last 13F report, Great Point Partners LLC shares in ‎the ‎company at filing stood at 1,966,688 shares, roughly $145,711,914.‎‎

SAGE Earnings Forecast For ‎The Current Quarter

Sage Therapeutics Inc. [SAGE] is expected ‎to report strong earnings results ‎for the quarter ending on Dec 2020. Consensus estimates give the ‎company expected revenues of ‎‎$55.34M and an earnings per share of -$0.45 for Dec 2020. Looking ‎further ahead, the company is ‎expected to report revenue of $174.85M at an EPS of $0.91 for Mar ‎‎2021. The estimates represent ‎upside of 311.40% and 60.40% in the company’s revenue and earnings ‎per share, respectively, on a ‎year-on-year basis.‎‎

Get the hottest stocks to trade every day before the ‎market opens 100% ‎free. Click here now. 

SAGE Earnings Estimates For ‎The Current ‎Year

For the financial year, Sage Therapeutics Inc. [NASDAQ:SAGE] is expected to ‎bring in ‎revenue of $57.75M. The returns are nearly $50.88 million higher than the company’s actual ‎revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -7.39, higher ‎than that ‎of FY19 by $5.99. Estimates put this year’s earnings growth at 44.80%, 60.40% for the next, ‎and at an ‎annual 41.40% over the next 5-year period. As for sales, forecasts are for an increase of ‎‎740.90% in the ‎current fiscal year and a further 311.40% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

SPX Flow Inc. (FLOW) stock surged during current market. Here’s why the stock is sky-rocketing?

SPX Flow Inc. (NASDAQ: FLOW) stock gained by 24.24% in the current market trading session. SPX FLOW, based in Charlotte, works to make the...

Platinum Group Metal Ltd. (PLG) stock surges during after-market trading. Here’s to know what’s happening?

Platinum Group Metal Ltd. (NASDAQ: PLG) stock declined by 8.54% at last close whereas the PLG stock price gains by 7% in the after-market...

17 Education & Technology Group Inc. (YQ) stock plummeting continues on Monday pre-market but why?

17 Education & Technology Group Inc. (YQ) stock has declined 21.28% as of this writing in Monday,s pre-market. In the regular trading session on...

Why did Protagenic Therapeutics Inc. (PTIX) stock commence the new week with a negative trend?

Protagenic Therapeutics Inc. (PTIX) shares declined 13.82% in the pre-market on Monday, July 26, 2021, as of this writing. In after-hours on Friday, Protagenic...

Acorda Therapeutics Inc. (ACOR) stock plunged during pre-market. Here’s what you should know.

Acorda Therapeutics Inc. (ACOR) stock rose by 24.15% at the last close whereas the ACOR stock price fell by 9.30% in the pre-market trading...

Related News

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%....

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...


Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free



Download Free eBook For


100% free. stop anytime no spam